Product Information
CARBIDOPA-LEVODOPA 25-250 TAB is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.1189 per EA under NDC 00093970310. Its NADAC has been published 133 times since Mar 20, 2024.
FDA first approved this application on Sep 3, 1993. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 250 mg/1; mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093970310
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBIDOPA HYDRATE; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA074260FDA Approved
9/3/1993
TE Code
AB
On Market Since
12/15/2023
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVODOPA 25-250 TAB has been published 133 times since Mar 20, 2024, and over the history we have for it it has declined 13.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1189 per EA |
|---|---|
| All-time high | $0.1424 (Oct 16, 2024) |
| All-time low | $0.0731 (Apr 17, 2024) |
| 52-week high | $0.1295 |
| 52-week low | $0.1085 |
| Median price | $0.1219 |
| Average price | $0.1199 |
| Largest weekly change | +71.8% (Jun 19, 2024) |
| Weeks tracked | 133 |
| Tracking since | Mar 20, 2024 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 7% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Carbidopa and levodopa market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatic Amino Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVODOPA 25-250 TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVODOPA 25-250 TAB, manufactured by Teva Pharmaceuticals USA Inc., is $0.1189 per EA (NDC 00093970310), effective Sep 30, 2026.
How has the price of CARBIDOPA-LEVODOPA 25-250 TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVODOPA 25-250 TAB has declined 13.0%. It has been tracked across 133 weekly CMS publications since Mar 20, 2024.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVODOPA 25-250 TAB?
Since Mar 20, 2024, the NADAC for CARBIDOPA-LEVODOPA 25-250 TAB has ranged from a low of $0.0731 (Apr 17, 2024) to a high of $0.1424 (Oct 16, 2024), with a median of $0.1219 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVODOPA 25-250 TAB?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CARBIDOPA-LEVODOPA 25-250 TAB, is $0.1104 per EA — about 7% below CARBIDOPA-LEVODOPA 25-250 TAB.
Who manufactures CARBIDOPA-LEVODOPA 25-250 TAB?
CARBIDOPA-LEVODOPA 25-250 TAB (NDC 00093970310) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.